Join the club for FREE to access the whole archive and other member benefits.

Phico Therapeutics

Biotechnology company developing a novel platform technology designed to overcome antibacterial resistance

At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPject™ could form the basis for a new generation of antibiotics to overcome antimicrobial resistance.

Visit website:



Details last updated 03-Oct-2019

Topics mentioned on this page:
Antibiotic Resistance